Both L-dopa and bromocriptine led to a significant reduction in LH levels in the hyperprolactinemic PCOS group compared to the normoprolactinemic subgroup (p < 0.01) and the control group (p < 0.05). Here, PLOD1 is linked to polycystic ovary syndrome.